EGFR and neoplasm: The seminal phase III clinical trial ACT IV investigating the use of Rindopepimut, a peptide vaccine targeting the EGFR deletion mutation EGFRvIII, plus temozolomide in newly diagnosed GBM in its failure to improve OS highlighted the limitation of single-antigen approach due to tumor heterogeneity and immune selection (51).